MG
FPRX

Michael Gelband’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Michael Gelband’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-54,094
Closed -$330K – 2419
2020
Q2 		$330K Buy
+54,094
New +$223K 0.01% 1276
2020
Q1 		– Sell
-19,683
Closed -$90K – 1858
2019
Q4 		$90K Buy
+19,683
New +$78K ﹤0.01% 1433
2019
Q3 		– Sell
-15,602
Closed -$94K – 1754
2019
Q2 		$94K Buy
+15,602
New +$149K ﹤0.01% 1025

Other funds holding FPRX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Michael Gelband's FPRX Position: Q3 2020 in Review

Michael Gelband sold out of Five Prime Therapeutics, Inc. (FPRX) in Q3 2020, closing a stake of 54,094 shares — an estimated $330K sold.

Michael Gelband first reported a position in FPRX in Q2 2019 and held it in 3 quarters. The position peaked at $330K in Q2 2020. 94 funds tracked by Wall St. Rank hold FPRX as of Q3 2020.

  • Michael Gelband reported no remaining Five Prime Therapeutics, Inc. position as of Q3 2020 after selling out during the quarter.
  • Michael Gelband sold 54,094 Five Prime Therapeutics, Inc. shares in Q3 2020, an estimated $330K.
  • Michael Gelband first reported a position in Five Prime Therapeutics, Inc. in Q2 2019 and held it in 3 quarters.
  • Michael Gelband's Five Prime Therapeutics, Inc. position peaked at $330K in Q2 2020.
  • 94 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q3 2020.

Based on ExodusPoint Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.